Syntax Advisors’s Spectrum Pharmaceuticals Inc SPPI Stock Holding History

Syntax Advisors’s Portfolio SPPI Stock Details SPPI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-29,181	Closed	-$37K	–	243
2021 Q4	$37K	Buy	+29,181	New	+$52.2K	0.03%	237

Other funds holding SPPI

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACM

Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return

Syntax Advisors's SPPI Position: Q1 2022 in Review

Syntax Advisors sold out of Spectrum Pharmaceuticals Inc (SPPI) in Q1 2022, closing a stake of 29,181 shares — an estimated $37K sold.

Syntax Advisors first reported a position in SPPI in Q4 2021 and held it in 1 quarter. The position peaked at $37K in Q4 2021. 101 funds tracked by Wall St. Rank hold SPPI as of Q1 2022.

Syntax Advisors reported no remaining Spectrum Pharmaceuticals Inc position as of Q1 2022 after selling out during the quarter.
Syntax Advisors sold 29,181 Spectrum Pharmaceuticals Inc shares in Q1 2022, an estimated $37K.
Syntax Advisors first reported a position in Spectrum Pharmaceuticals Inc in Q4 2021 and held it in 1 quarter.
Syntax Advisors's Spectrum Pharmaceuticals Inc position peaked at $37K in Q4 2021.
101 funds tracked by Wall St. Rank held Spectrum Pharmaceuticals Inc as of Q1 2022.

Based on Syntax Advisors's 13F filing for Q1 2022, filed 11 May 2022.